Literature DB >> 8908701

Targeting of peripheral blood T lymphocytes.

R L Bolhuis1, H R Hoogenboom, J W Gratama.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8908701     DOI： 10.1007/bf00820667

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  117 in total

1.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.

Authors:  H R Hoogenboom; A D Griffiths; K S Johnson; D J Chiswell; P Hudson; G Winter
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

2.  CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells.

Authors:  G Sconocchia; J A Titus; D M Segal
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

3.  Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.

Authors:  M A Garrido; M J Valdayo; D F Winkler; J A Titus; T T Hecht; P Perez; D M Segal; J R Wunderlich
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.

Authors:  C Demanet; J Brissinck; O Leo; M Moser; K Thielemans
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.

Authors:  J G Tibben; O C Boerman; R A Claessens; F H Corstens; M van Deuren; P H de Mulder; J W van der Meer; K G Keijser; L F Massuger
Journal:  J Natl Cancer Inst       Date:  1993-06-16       Impact factor: 13.506

Review 6.  Internal disintegration model of cytotoxic lymphocyte-induced target damage.

Authors:  J H Russell
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

7.  Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.

Authors:  J A Titus; M A Garrido; T T Hecht; D F Winkler; J R Wunderlich; D M Segal
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

Review 8.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli.

Authors:  P Pack; A Plückthun
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

10.  Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab')2 antibody prolong host survival in a murine xenograft model.

Authors:  D Mezzanzanica; M A Garrido; D S Neblock; P E Daddona; S M Andrew; V R Zurawski; D M Segal; J R Wunderlich
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701
View more
  2 in total

Review 1.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.

Authors:  P Bühler; P Wolf; D Gierschner; I Schaber; A Katzenwadel; W Schultze-Seemann; U Wetterauer; M Tacke; M Swamy; W W A Schamel; U Elsässer-Beile
Journal:  Cancer Immunol Immunother       Date:  2007-06-20       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.